[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
July 23 2008

This Week in JAMA

JAMA. 2008;300(4):363. doi:10.1001/jama.300.4.363

Patients who take selective and nonselective serotonin reuptake inhibitors (SRIs) for depression often report treatment-related sexual dysfunction. Selective phosphodiesterase type 5 inhibitors, such as sildenafil, have proven efficacy in the treatment of sexual dysfunction in men, including men with depression, but these agents have received limited study in women. To evaluate the efficacy of sildenafil among women with SRI-associated sexual dysfunction, Nurnberg and colleagues randomly assigned 98 premenopausal women, whose depression was remitted by SRIs but who were experiencing sexual dysfunction since the onset of their depression or antidepressant treatment, to take either sildenafil or placebo before sexual activity. The authors found that compared with those receiving placebo, women who were treated with sildenafil had significant improvement in sexual function during the 8-week trial.

×